Compare Ares Capital Corporation (ARCC) vs Oscar Health Inc (OSCR) Price & Performance

ARCC trades at $19.98, down 0.15% on the day, with a P/E of 14.9 and P/B of 1.03. Recent quarterly earnings have consistently missed expectations, with Q2 2026 EPS of $0.47 falling short of the $0.4731 estimate. Technical indicators show a bullish moving average signal but bearish oscillators, with RSI at 78.37 suggesting overbought conditions. The company maintains a strong dividend yield of approximately 9.6% with consistent $0.48 quarterly payments.

While ARCC offers attractive income with its high dividend yield and strong analyst support (24 buy ratings), investors face risks from declining revenue trends and compressed earnings. The stock trades near consensus price targets, limiting near-term upside potential. Credit quality concerns in the private lending sector and potential interest rate sensitivity present additional headwinds for this business development company.

OSCR trades at $27.97, up 1.08% today, with a bearish technical signal but strong recent earnings beats in Q1 and Q2 2026. The company reported record profitability and raised its full-year outlook, driven by membership growth and cost controls. Key support lies at $26, with resistance at $28. Revenue surged 70% year-over-year in H1 2026 to $4.9 billion, per PYMNTS on August 6, 2026.

Outlook is positive due to robust growth and margin expansion, but risks include execution challenges and competitive pressures. Analysts have a consensus price target of $32.50, with 27% buy ratings. The stock offers value with a P/S of 0.53, though net income volatility remains a concern.